191 related articles for article (PubMed ID: 30723888)
1. Model-Informed Drug Development Approach to Expedite Approval: Case of Alectinib in First-Line Anaplastic Lymphoma Kinase + Non-Small Cell Lung Cancer.
Morcos PN; Liu J; Blumenthal GM; Zhao H
Clin Pharmacol Ther; 2019 Apr; 105(4):826-828. PubMed ID: 30723888
[No Abstract] [Full Text] [Related]
2. Alectinib: A Review in Advanced, ALK-Positive NSCLC.
Paik J; Dhillon S
Drugs; 2018 Aug; 78(12):1247-1257. PubMed ID: 30030733
[TBL] [Abstract][Full Text] [Related]
3. Personalized Medicine Tackles Clinical Resistance: Alectinib in ALK-Positive Non-Small Cell Lung Cancer Progressing on First-Generation ALK Inhibitor.
Skoulidis F; Papadimitrakopoulou VA
Clin Cancer Res; 2016 Nov; 22(21):5177-5182. PubMed ID: 27609840
[TBL] [Abstract][Full Text] [Related]
4. FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib.
Larkins E; Blumenthal GM; Chen H; He K; Agarwal R; Gieser G; Stephens O; Zahalka E; Ringgold K; Helms W; Shord S; Yu J; Zhao H; Davis G; McKee AE; Keegan P; Pazdur R
Clin Cancer Res; 2016 Nov; 22(21):5171-5176. PubMed ID: 27413075
[TBL] [Abstract][Full Text] [Related]
5. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Gadgeel SM
Future Oncol; 2018 Aug; 14(18):1875-1882. PubMed ID: 29536761
[TBL] [Abstract][Full Text] [Related]
6. Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer.
Carlson JJ; Suh K; Orfanos P; Wong W
Pharmacoeconomics; 2018 Apr; 36(4):495-504. PubMed ID: 29488070
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort.
Bedas A; Peled N; Maimon Rabinovich N; Mishaeli M; Shochat T; Zer A; Rotem O; Allen AM; Bar J; Dudnik E;
Oncol Res Treat; 2019; 42(5):275-282. PubMed ID: 30955009
[TBL] [Abstract][Full Text] [Related]
8. Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer.
Hirota T; Muraki S; Ieiri I
Clin Pharmacokinet; 2019 Apr; 58(4):403-420. PubMed ID: 29915924
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib.
Davies J; Martinec M; Delmar P; Coudert M; Bordogna W; Golding S; Martina R; Crane G
J Comp Eff Res; 2018 Sep; 7(9):855-865. PubMed ID: 29944008
[TBL] [Abstract][Full Text] [Related]
10. Successful re-introduction of alectinib after inducing interstitial lung disease in a patient with lung cancer.
Hwang A; Iskandar A; Dasanu CA
J Oncol Pharm Pract; 2019 Sep; 25(6):1531-1533. PubMed ID: 30572795
[TBL] [Abstract][Full Text] [Related]
11. Severe Acute Hepatitis in a Patient Receiving Alectinib for ALK-Positive Non-Small-Cell Lung Cancer: Histologic Analysis.
Zhu VW; Lu Y; Ou SI
Clin Lung Cancer; 2019 Jan; 20(1):e77-e80. PubMed ID: 30318176
[No Abstract] [Full Text] [Related]
12. Adjuvant alectinib improves outcomes in ALK-mutant NSCLC.
Romero D
Nat Rev Clin Oncol; 2024 Jul; 21(7):484. PubMed ID: 38664533
[No Abstract] [Full Text] [Related]
13. Targeted Therapy With Anaplastic Lymphoma Kinase Inhibitor (Alectinib) in Adolescent Metastatic Non-Small Cell Lung Carcinoma: 18F-NaF PET/CT in Response Evaluation.
Usmani S; Marafi F; Rasheed R; Al Maraghy M; Al Kandari F
Clin Nucl Med; 2018 Oct; 43(10):752-754. PubMed ID: 30059431
[TBL] [Abstract][Full Text] [Related]
14. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Peters S; Camidge DR; Shaw AT; Gadgeel S; Ahn JS; Kim DW; Ou SI; Pérol M; Dziadziuszko R; Rosell R; Zeaiter A; Mitry E; Golding S; Balas B; Noe J; Morcos PN; Mok T;
N Engl J Med; 2017 Aug; 377(9):829-838. PubMed ID: 28586279
[TBL] [Abstract][Full Text] [Related]
15. Successful oral desensitization against skin rash induced by alectinib in a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma: A case report.
Shirasawa M; Kubotaa M; Harada S; Niwa H; Kusuhara S; Kasajima M; Hiyoshi Y; Ishihara M; Igawa S; Masuda N
Lung Cancer; 2016 Sep; 99():66-8. PubMed ID: 27565916
[TBL] [Abstract][Full Text] [Related]
16. [Discovery and development of alectinib hydrochloride (ALECENSAR capsule 20 mg and 40 mg)
].
Yoshimura Y; Sakamoto H; Tanaka T; Inagaki N; Uzu M
Nihon Yakurigaku Zasshi; 2015 Jun; 145(6):318-24. PubMed ID: 26063155
[No Abstract] [Full Text] [Related]
17. Case Report of Non-Small Cell Lung Cancer with STRN-ALK Translocation: A Nonresponder to Alectinib.
Nakanishi Y; Masuda S; Iida Y; Takahashi N; Hashimoto S
J Thorac Oncol; 2017 Dec; 12(12):e202-e204. PubMed ID: 29169525
[No Abstract] [Full Text] [Related]
18. Enteral administration of alectinib for ALK-positive non-small cell lung cancer in an elderly patient: A case report.
Thomas QD; Pautas M; Guilhaume MN; Fiteni F; Ge T; Girard N
Medicine (Baltimore); 2021 Oct; 100(43):e27611. PubMed ID: 34713842
[TBL] [Abstract][Full Text] [Related]
19. Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from Alectinib.
Ren C; Sun N; Kong Y; Qu X; Liu H; Zhong H; Song X; Yang X; Jiang B
Eur J Med Chem; 2021 May; 217():113335. PubMed ID: 33751979
[TBL] [Abstract][Full Text] [Related]
20. Safety and Tolerability of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer.
Rocco D; Battiloro C; Della Gravara L; Gridelli C
Drug Saf; 2019 Feb; 42(2):199-209. PubMed ID: 30649741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]